Difference between revisions of "Part:BBa K5301018"

 
(7 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K5301018 short</partinfo>
 
<partinfo>BBa_K5301018 short</partinfo>
  
sGFP11 tether is composed of mSA, a 3C linker, a 6His tag, and sGFP11.We construct membrane protein dimers through the interaction between biotin and streptavidin, as well as the self-assembly mechanism of sGFP.
+
sGFP11 tether is composed of mSA (<partinfo>BBa_K4623001</partinfo>), a 3C linker, a 6 His tag, and sGFP11 (<partinfo>BBa_K5301014</partinfo>).We construct membrane protein dimers through the interaction between biotin and streptavidin, as well as the self-assembly mechanism of sGFP.
  
===Usage and Biology===
+
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.2;overflow:hidden;">
 +
https://static.igem.wiki/teams/5301/parts/sgfp11-tether-structure.png
 +
</div><div class="thumbcaption">
 +
Figure 1.AlphaFold2 predition of the sGFP11 tether
 +
</div></div></div></div>
 +
 
 +
 
 +
==Usage and Biology==
  
 
mSA is used for binding to biotinylated proteins, and sGFP1-10 and sGFP11 self-assemble to form GFP, thereby creating a protein dimer that can report the outcome with fluorescence.
 
mSA is used for binding to biotinylated proteins, and sGFP1-10 and sGFP11 self-assemble to form GFP, thereby creating a protein dimer that can report the outcome with fluorescence.
  
===Characterization===  
+
==Characterization==
==PCR==
+
===PCR===
We conducted colony PCR validation to assess the feasibility of the plasmid pathway, as shown in Figure 1, where the corresponding bands are very clear, indicating that the target fragments were successfully introduced into the plasmid and transformed into the bacterial strain.
+
We conducted colony PCR validation to assess the feasibility of the plasmid pathway, as shown in Figure 2, where the corresponding bands are very clear, indicating that the target fragments were successfully introduced into the plasmid and transformed into the bacterial strain.
  
 
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.6;overflow:hidden;">
 
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.6;overflow:hidden;">
 
https://static.igem.wiki/teams/5301/parts/sgfp11-pcr.png
 
https://static.igem.wiki/teams/5301/parts/sgfp11-pcr.png
 
</div><div class="thumbcaption">
 
</div><div class="thumbcaption">
Figure 1.PCR result of the sGFP11 tether.The base sequence length of the sGFP11 tether is 477 base pairs (bp)
+
Figure 2.PCR result of the sGFP11 tether.The base sequence length of the sGFP11 tether is 477 base pairs (bp)
 
</div></div></div></div>
 
</div></div></div></div>
  
==SDS-PAGE==
+
===SDS-PAGE===
SDS-PAGE was used to verify the purification of the sGFP11 tether. Due to the particularity of mSA, we simultaneously purified the soluble proteins from the supernatant and the inclusion body proteins from the pellet after bacterial lysis. It can be observed that the concentration and purity of the purified inclusion body proteins are high, while the concentration of the soluble proteins is low. Further exploration of soluble protein expression or assessment of inclusion body protein activity can be conducted subsequently.
+
SDS-PAGE was used to verify the purification of the sGFP11 tether.Based on the experience with the sGFP1-10 tether, we purified the soluble and inclusion body proteins of the sGFP11 tether, as depicted in Figure 3.
Based on the experience with the sGFP1-10 tether, we have purified the soluble and inclusion body proteins of the sGFP11 tether, as shown in Figure 2.  
+
  
 
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.5;overflow:hidden;">
 
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.5;overflow:hidden;">
 
https://static.igem.wiki/teams/5301/parts/sgfp1-11-sds.png
 
https://static.igem.wiki/teams/5301/parts/sgfp1-11-sds.png
 
</div><div class="thumbcaption">
 
</div><div class="thumbcaption">
Figure 2.SDS-PAGE of the soluble sGFP11 tether.The molecular weight of the sGFP11 tether is 17.0 kDa. Bands 4 and 5 represent the elution results of the sGFP11 tether with 100 mM and 150 mM imidazole, respectively. It can be observed that the concentration of the protein eluted with 100 mM imidazole is higher.
+
Figure 3.SDS-PAGE of the soluble sGFP11 tether.The molecular weight of the sGFP11 tether is 17.0 kDa. Bands 4 and 5 represent the elution results of the sGFP11 tether with 100 mM and 150 mM imidazole, respectively. It can be observed that the concentration of the protein eluted with 100 mM imidazole is higher.
 
</div></div></div></div>
 
</div></div></div></div>
  
==ELISA==
+
===ELISA===
We conducted an activity analysis of sGFP tethers. Using the standard interaction between streptavidin and biotin as a control, we observed the interaction between the expressed protein and biotin to determine the activity of the expressed sGFP tether. Observations from Figure 1 indicate that the directly purified soluble sGFP tether exhibits some activity, while the inclusion body proteins, after purification through denaturation and refolding, do not exhibit activity.
+
We conducted an activity analysis of sGFP tethers. Using the standard interaction between streptavidin and biotin as a control, we observed the interaction between the expressed protein and biotin to determine the activity of the expressed sGFP tether. Observations from Figure 4 indicated that the directly purified soluble sGFP11 tether exhibited some activity, while the inclusion body proteins, after purification through denaturation and refolding, didn't exhibit activity.
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:1.0;overflow:hidden;">
+
<div class="center"><div class="thumb tnone"><div class="thumbinner" style="width:min-content;"><div style="zoom:0.15;overflow:hidden;">
https://static.igem.wiki/teams/5301/parts/elisa.png
+
https://static.igem.wiki/teams/5301/parts/elisa-2.png
 
</div><div class="thumbcaption">
 
</div><div class="thumbcaption">
Figure 1.ELISA of the expressed mSA(present in the form of sGFP tether).
+
Figure 4.ELISA of sGFP11 tether.
 
Row A, wells 1-9 contain a gradient of mSA standard solutions, while wells 10 and 11 are negative controls with 0.5% BSA.  
 
Row A, wells 1-9 contain a gradient of mSA standard solutions, while wells 10 and 11 are negative controls with 0.5% BSA.  
 
Row B, wells 1-10 also contain a gradient of mSA standard solutions, and wells 11 and 12 are negative controls with 0.5% BSA.  
 
Row B, wells 1-10 also contain a gradient of mSA standard solutions, and wells 11 and 12 are negative controls with 0.5% BSA.  
Row C, wells 1 and 4 are refolded samples of sGFP1-10 tether protein, while wells 2 and 5 are refolded samples of sGFP11 tether protein. Row D, well 1 contains purified samples of sGFP1-10 tether protein, and well 2 contains purified samples of sGFP11 tether protein.  
+
Row C, wells 2 and 5 are refolded samples of sGFP11 tether protein.  
Rows E and F, well 1 contains purified inclusion body samples of sGFP11 tether, and well 2 contains purified inclusion body samples of sGFP1-10 tether.
+
Row D, well 2 contains purified samples of sGFP11 tether protein.  
 +
Rows E and F, well 1 contains purified inclusion body samples of sGFP11 tether.
 
</div></div></div></div>
 
</div></div></div></div>
  
Line 45: Line 52:
  
 
<!-- -->
 
<!-- -->
===Sequence and Features===
+
==Sequence and Features==
 
<partinfo>BBa_K5301018 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K5301018 SequenceAndFeatures</partinfo>
  

Latest revision as of 09:40, 2 October 2024


sGFP11 tether is composed of mSA, a 3C linker, a 6His tag, and sGFP 11.

sGFP11 tether is composed of mSA (BBa_K4623001), a 3C linker, a 6 His tag, and sGFP11 (BBa_K5301014).We construct membrane protein dimers through the interaction between biotin and streptavidin, as well as the self-assembly mechanism of sGFP.

sgfp11-tether-structure.png

Figure 1.AlphaFold2 predition of the sGFP11 tether


Usage and Biology

mSA is used for binding to biotinylated proteins, and sGFP1-10 and sGFP11 self-assemble to form GFP, thereby creating a protein dimer that can report the outcome with fluorescence.

Characterization

PCR

We conducted colony PCR validation to assess the feasibility of the plasmid pathway, as shown in Figure 2, where the corresponding bands are very clear, indicating that the target fragments were successfully introduced into the plasmid and transformed into the bacterial strain.

sgfp11-pcr.png

Figure 2.PCR result of the sGFP11 tether.The base sequence length of the sGFP11 tether is 477 base pairs (bp)

SDS-PAGE

SDS-PAGE was used to verify the purification of the sGFP11 tether.Based on the experience with the sGFP1-10 tether, we purified the soluble and inclusion body proteins of the sGFP11 tether, as depicted in Figure 3.

sgfp1-11-sds.png

Figure 3.SDS-PAGE of the soluble sGFP11 tether.The molecular weight of the sGFP11 tether is 17.0 kDa. Bands 4 and 5 represent the elution results of the sGFP11 tether with 100 mM and 150 mM imidazole, respectively. It can be observed that the concentration of the protein eluted with 100 mM imidazole is higher.

ELISA

We conducted an activity analysis of sGFP tethers. Using the standard interaction between streptavidin and biotin as a control, we observed the interaction between the expressed protein and biotin to determine the activity of the expressed sGFP tether. Observations from Figure 4 indicated that the directly purified soluble sGFP11 tether exhibited some activity, while the inclusion body proteins, after purification through denaturation and refolding, didn't exhibit activity.

elisa-2.png

Figure 4.ELISA of sGFP11 tether. Row A, wells 1-9 contain a gradient of mSA standard solutions, while wells 10 and 11 are negative controls with 0.5% BSA. Row B, wells 1-10 also contain a gradient of mSA standard solutions, and wells 11 and 12 are negative controls with 0.5% BSA. Row C, wells 2 and 5 are refolded samples of sGFP11 tether protein. Row D, well 2 contains purified samples of sGFP11 tether protein. Rows E and F, well 1 contains purified inclusion body samples of sGFP11 tether.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 82
    Illegal AgeI site found at 142
  • 1000
    COMPATIBLE WITH RFC[1000]